These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 32005303)
1. Performance-based technical support for drug-resistant TB responses: lessons from the Green Light Committee. Yassin MA; Samson K; Wandwalo E; Grzemska M; Gegia M; Nwaneri N; Hansen P; Kunii O Int J Tuberc Lung Dis; 2020 Jan; 24(1):22-27. PubMed ID: 32005303 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool. Migliori GB; Sotgiu G; Jaramillo E; Mirzayev F; Centis R; Colvin C; Richardson MD Int J Tuberc Lung Dis; 2009 Oct; 13(10):1305-8. PubMed ID: 19793438 [TBL] [Abstract][Full Text] [Related]
4. Multi-drug resistant tuberculosis burden and risk factors: an update. Marahatta SB Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520 [TBL] [Abstract][Full Text] [Related]
5. The Bedaquiline Donation Program: progress and lessons learned after 4 years of implementation. Rutta E; Kambili C; Mukadi Y Int J Tuberc Lung Dis; 2020 Oct; 24(10):1039-1045. PubMed ID: 33126936 [TBL] [Abstract][Full Text] [Related]
6. Addressing the drug-resistant tuberculosis challenge through implementing a mixed model of care in Uganda. Kasozi S; Kirirabwa NS; Kimuli D; Luwaga H; Kizito E; Turyahabwe S; Lukoye D; Byaruhanga R; Chen L; Suarez P PLoS One; 2020; 15(12):e0244451. PubMed ID: 33373997 [TBL] [Abstract][Full Text] [Related]
7. No universal access to drug-resistant tuberculosis care without engaging all health care providers. Linh NN; Wares F; Cocozza AM; Uplekar M; Raviglione M Int J Tuberc Lung Dis; 2020 Jan; 24(1):118-123. PubMed ID: 32005315 [TBL] [Abstract][Full Text] [Related]
8. Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis. Nathavitharana RR; Lederer P; Tierney DB; Nardell E Int J Tuberc Lung Dis; 2019 Apr; 23(4):396-404. PubMed ID: 31064617 [TBL] [Abstract][Full Text] [Related]
9. Overcoming challenges in the diagnosis, prevention, and treatment of pediatric drug-resistant tuberculosis. Jonckheree S; Furin J Expert Rev Respir Med; 2017 May; 11(5):385-394. PubMed ID: 28319425 [TBL] [Abstract][Full Text] [Related]
10. Improving diagnosis and case management of patients with tuberculosis: A review of gaps, needs and potential solutions in accessing laboratory diagnostics. Andama A; Somoskovi A; Mandel B; Bell D; Gutierrez C Infect Genet Evol; 2019 Aug; 72():131-140. PubMed ID: 30326281 [TBL] [Abstract][Full Text] [Related]
11. Programmes and principles in treatment of multidrug-resistant tuberculosis. Mukherjee JS; Rich ML; Socci AR; Joseph JK; Virú FA; Shin SS; Furin JJ; Becerra MC; Barry DJ; Kim JY; Bayona J; Farmer P; Smith Fawzi MC; Seung KJ Lancet; 2004 Feb; 363(9407):474-81. PubMed ID: 14962530 [TBL] [Abstract][Full Text] [Related]
12. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas. Bernal O; Lopez R; Montoro E; Avedillo P; Westby K; Ghidinelli M Int J Tuberc Lung Dis; 2020 Oct; 24(10):1058-1062. PubMed ID: 33126939 [TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities for eliminating tuberculosis - leveraging political momentum of the UN high-level meeting on tuberculosis. Sakamoto H; Lee S; Ishizuka A; Hinoshita E; Hori H; Ishibashi N; Komada K; Norizuki M; Katsuma Y; Akashi H; Shibuya K BMC Public Health; 2019 Jan; 19(1):76. PubMed ID: 30651096 [TBL] [Abstract][Full Text] [Related]
14. What will it take to eliminate drug-resistant tuberculosis? Kendall EA; Sahu S; Pai M; Fox GJ; Varaine F; Cox H; Cegielski JP; Mabote L; Vassall A; Dowdy DW Int J Tuberc Lung Dis; 2019 May; 23(5):535-546. PubMed ID: 31097060 [TBL] [Abstract][Full Text] [Related]
15. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Albert H; Nathavitharana RR; Isaacs C; Pai M; Denkinger CM; Boehme CC Eur Respir J; 2016 Aug; 48(2):516-25. PubMed ID: 27418550 [TBL] [Abstract][Full Text] [Related]
16. Multidrug-Resistant Tuberculosis in the End Tuberculosis EraMultidrug-Resistant Tuberculosis in the End Tuberculosis Era. Cegielski JP Rev Peru Med Exp Salud Publica; 2018; 35(1):110-117. PubMed ID: 29924256 [TBL] [Abstract][Full Text] [Related]
17. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. Fears R; Kaufmann S; Ter Meulen V; Zumla A; Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566 [TBL] [Abstract][Full Text] [Related]
18. Increasing transparency in partnerships for health--introducing the Green Light Committee. Gupta R; Cegielski JP; Espinal MA; Henkens M; Kim JY; Lambregts-Van Weezenbeek CS; Lee JW; Raviglione MC; Suarez PG; Varaine F Trop Med Int Health; 2002 Nov; 7(11):970-6. PubMed ID: 12390604 [TBL] [Abstract][Full Text] [Related]